Body Part, Organ, or Organ Component – Page 3

Strategic Roadmap for Biologics Manufacturing: Enhancing Efficiency and Flexibility

6 months ago talkbio0Tagged Biological Factors, biomanufacturing, bony process, Characterization, Continuous, Efficiency, Manufacturing, Modular Facilities, Pliability, Precision medicines, Regulatory Compliance, Strategic Roadmap, technology roadmap

Biologics manufacturing, Strategic roadmap, Process characterization, Flexibility and efficiency, Regulatory compliance, Biomanufacturing technology roadmap, Precision medicines, Modular facilities, Continuous manufacturing

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

6 months ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

6 months ago talkbio0Tagged BeiGene, Cancer Therapeutic Procedure, Commission approval, European (ethnic group), first-line, Gastroesophageal Junction Adenocarcinoma, Squamous cell carcinoma of esophagus, Stomach, Tevimbra, tislelizumab

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

Bayer Secures Exclusive Rights to Aficamten in Japan Through Licensing Agreement with Cytokinetics

7 months ago talkbio0Tagged Aficamten, Bayer, Cytokinetics, Heart, Hypertrophic Cardiomyopathy, Japan, licensing agreement, myosin inhibitor

Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor

Bayer’s Q3 Earnings Plummet 37%, CEO Urges Patience Amid Performance-Boosting Strategy

7 months ago talkbio0Tagged Avian crop, Bayer, Bill Anderson, CEO, decline, earnings, generics, Kerendia, Nubeqa, performance-boosting strategy

Bayer, Q3 earnings, decline, CEO Bill Anderson, performance-boosting strategy, pharmaceuticals, crop science, generics, Xarelto, Nubeqa, Kerendia.

The Evolution of Smart Drugs: Enhancing Cognitive Performance and Beyond

7 months ago talkbio0Tagged Biohacking, Brain, cognitive enhancement, cognitive supplements, Neuronal Plasticity, Nootropic Agents, Optimization, smart drugs

Smart drugs, nootropics, cognitive enhancement, biohacking, brain performance, cognitive supplements, neuroplasticity, brain optimization.

Abbott’s Esprit BTK Stent Demonstrates Sustained Benefits in Treating Severe Peripheral Artery Disease Below the Knee

7 months ago talkbio0Tagged abbott, BTK gene, Chronic Limb-Threatening Ischemia, dissolving stent, Esapent, Knee, LIFE-BTK trial, Peripheral Arterial Diseases, vascular health

Esprit BTK, dissolving stent, peripheral artery disease, below the knee, chronic limb-threatening ischemia, Abbott, LIFE-BTK trial, vascular health

Sinaptica’s Neuromodulation Therapy Demonstrates 44% Reduction in Alzheimer’s Disease Progression

7 months ago talkbio0Tagged Alzheimer 's disease, Default Mode Network, Disease Progression, neuromodulation therapy, Non-invasive therapy, Personalized Treatment, Sinaptica, Stimulation procedure, Structure of precuneus

Sinaptica Therapeutics, Neuromodulation therapy, Alzheimer’s disease, Disease progression reduction, Personalized treatment, Non-invasive therapy, Default Mode Network (DMN), Precuneus stimulation

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

7 months ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition

Mitigating Risks in mRNA Manufacturing: Strategies for Smooth Transition from Preclinical to Clinical Stages

8 months ago talkbio0Tagged analytical method, Automation, bony process, clinical transition, Control Groups, Materials, Preclinical, Quality, regulatory, Risk Management, RNA, Messenger

mRNA manufacturing, risk management, preclinical to clinical transition, quality control, regulatory compliance, raw material selection, process automation, analytical methods.